Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1981 1
1982 1
1983 1
1984 1
1986 1
1987 2
1989 2
1990 2
1991 1
1993 1
1995 1
1997 4
1999 2
2000 2
2001 1
2002 1
2004 2
2008 3
2009 2
2010 1
2011 2
2012 2
2013 2
2015 4
2016 2
2017 4
2018 7
2019 7
2020 5
2021 7
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Advanced Undifferentiated Pleomorphic Sarcoma"
Page 1
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Tawbi HA, et al. Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Lancet Oncol. 2017. PMID: 28988646 Free PMC article. Clinical Trial.
Median follow-up was 17.8 months (IQR 12.3-19.3). Seven (18%) of 40 patients with soft-tissue sarcoma had an objective response, including four (40%) of ten patients with undifferentiated pleomorphic sarcoma, two (20%) of ten patients with liposarcoma, …
Median follow-up was 17.8 months (IQR 12.3-19.3). Seven (18%) of 40 patients with soft-tissue sarcoma had an objective response, incl …
Options for treating different soft tissue sarcoma subtypes.
Ray-Coquard I, Serre D, Reichardt P, Martín-Broto J, Bauer S. Ray-Coquard I, et al. Future Oncol. 2018 May;14(10s):25-49. doi: 10.2217/fon-2018-0076. Future Oncol. 2018. PMID: 29768052 Review.
Management of soft tissue sarcoma is increasingly subtype-dependent. Surgery is recommended for uterine leiomyosarcoma, with trabectedin being the preferred option for advanced disease when the treatment goal is long-term tumor stabilization. Liposarcoma subgroups a …
Management of soft tissue sarcoma is increasingly subtype-dependent. Surgery is recommended for uterine leiomyosarcoma, with trabecte …
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Somaiah N, et al. Lancet Oncol. 2022 Sep;23(9):1156-1166. doi: 10.1016/S1470-2045(22)00392-8. Epub 2022 Aug 4. Lancet Oncol. 2022. PMID: 35934010 Clinical Trial.
METHODS: In this single-centre phase 2 trial, done at The University of Texas MD Anderson Cancer Center (Houston, TX USA), patients aged 18 years or older with advanced or metastatic sarcoma with an Eastern Cooperative Oncology Group performance status of 0 o …
METHODS: In this single-centre phase 2 trial, done at The University of Texas MD Anderson Cancer Center (Houston, TX USA), patients a …
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
Demetri GD, Luke JJ, Hollebecque A, Powderly JD 2nd, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher A, Villalobos VM. Demetri GD, et al. Clin Cancer Res. 2021 Jul 1;27(13):3556-3566. doi: 10.1158/1078-0432.CCR-20-4513. Epub 2021 Apr 5. Clin Cancer Res. 2021. PMID: 33820780 Clinical Trial.
Herein, we report findings of ABBV-085 monotherapy or combination therapy in adult patients with sarcomas and other advanced solid tumors. PATIENTS AND METHODS: This first-in-human phase I study (NCT02565758) assessed ABBV-085 safety, pharmacokinetics/pharmacodynamics, and …
Herein, we report findings of ABBV-085 monotherapy or combination therapy in adult patients with sarcomas and other advanced solid tu …
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma.
Kelly CM, Qin LX, Whiting KA, Richards AL, Avutu V, Chan JE, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Adamson T, Singer S, Bartlett EK, Crago AM, Yoon SS, Hwang S, Erinjeri JP, Antonescu CR, Tap WD, D'Angelo SP. Kelly CM, et al. Clin Cancer Res. 2023 Jun 1;29(11):2043-2051. doi: 10.1158/1078-0432.CCR-22-3911. Clin Cancer Res. 2023. PMID: 36971773 Free PMC article. Clinical Trial.
PURPOSE: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, whi …
PURPOSE: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward an immune-stimulated …
Dedifferentiated gastrointestinal stromal tumor: Recent advances.
Karakas C, Christensen P, Baek D, Jung M, Ro JY. Karakas C, et al. Ann Diagn Pathol. 2019 Apr;39:118-124. doi: 10.1016/j.anndiagpath.2018.12.005. Epub 2018 Dec 18. Ann Diagn Pathol. 2019. PMID: 30661742 Review.
GISTs can present with various morphologies including rhabdomyosarcoma, angiosarcoma, or undifferentiated pleomorphic sarcoma. The unusual histologic and immunohistochemical characteristics of these tumors can be diagnostically challenging. ...
GISTs can present with various morphologies including rhabdomyosarcoma, angiosarcoma, or undifferentiated pleomorphic sarco …
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
Tang F, Tie Y, Wei YQ, Tu CQ, Wei XW. Tang F, et al. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188606. doi: 10.1016/j.bbcan.2021.188606. Epub 2021 Aug 8. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34371128 Free article. Review.
Sarcomas represent a distinct group of rare malignant tumors with high heterogeneity. Limited options with clinical efficacy for the metastatic or local advanced sarcoma existed despite standard therapy. ...Immunotherapy represents a promising and favo …
Sarcomas represent a distinct group of rare malignant tumors with high heterogeneity. Limited options with clinical efficacy f …
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
Albarrán V, Villamayor ML, Chamorro J, Rosero DI, Pozas J, San Román M, Calvo JC, Pérez de Aguado P, Moreno J, Guerrero P, González C, García de Quevedo C, Álvarez-Ballesteros P, Vaz MÁ. Albarrán V, et al. Int J Mol Sci. 2022 Nov 9;23(22):13784. doi: 10.3390/ijms232213784. Int J Mol Sci. 2022. PMID: 36430263 Free PMC article. Review.
Osteosarcoma (OS) is the most frequent primary bone tumor and several TKIs have demonstrated clinical benefit in phase II clinical trials (cabozantinib, regorafenib, apatinib, sorafenib, and lenvatinib). Although the development of TKIs for other primary bone tumors …
Osteosarcoma (OS) is the most frequent primary bone tumor and several TKIs have demonstrated clinical benefit in phase II clinical …
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT, Shenasa E, Nielsen TO. Zhu MMT, et al. Cancer Treat Rev. 2020 Dec;91:102115. doi: 10.1016/j.ctrv.2020.102115. Epub 2020 Oct 20. Cancer Treat Rev. 2020. PMID: 33130422 Free article. Review.
New technologies such as multiplex immunohistochemistry and high plex in situ profiling may offer more insights into the sarcoma microenvironment. To date, clinical trials using immune checkpoint inhibitor monotherapy have not shown compelling clinical benefi …
New technologies such as multiplex immunohistochemistry and high plex in situ profiling may offer more insights into the sarcoma micr …
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.
Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. Roland CL, et al. Nat Cancer. 2024 Apr;5(4):625-641. doi: 10.1038/s43018-024-00726-z. Epub 2024 Feb 13. Nat Cancer. 2024. PMID: 38351182 Clinical Trial.
Based on the demonstrated clinical activity of immune-checkpoint blockade (ICB) in advanced dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS), we conducted a randomized, non-comparative phase 2 trial …
Based on the demonstrated clinical activity of immune-checkpoint blockade (ICB) in advanced dedifferentiated liposarcoma (DDLP …
79 results